Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis

Published:2021-12-01 Issue:1 Volume:39 Page:165-177
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Di Nunno Vincenzo,Franceschi Enrico^ORCID,Tosoni Alicia,Gatto Lidia,Maggio Ilaria,Lodi Raffaele,Angelini Daniele,Bartolini Stefania,Brandes Alba Ariela

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-01977-3.pdf

Reference30 articles.

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1.

2. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21(Suppl 5):v1–100. https://doi.org/10.1093/neuonc/noz150.

3. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–86. https://doi.org/10.1038/s41571-020-00447-z.

4. Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–98. https://doi.org/10.1056/NEJMoa1402121.

5. Mair MJ, Geurts M, van den Bent MJ, Berghoff AS. A basic review on systemic treatment options in WHO grade II-III gliomas. Cancer Treat Rev. 2021;92: 102124. https://doi.org/10.1016/j.ctrv.2020.102124.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Catalytically distinct IDH1 mutants tune phenotype severity in tumor models;2024-04-23

2. Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma;Acta Neuropathologica;2024-01-06

3. Integrated analysis reveals CP is a potential biomarker and therapeutic target in glioma;2023-07-14

4. Preoperative neurocognitive function as an independent survival prognostic marker in primary glioblastoma;Neuro-Oncology Practice;2023-05-11

5. Noncanonical (Non-R132H) IDH-Mutated Gliomas;Glioblastoma - Current Evidence;2023-03-29